Tuberculosis continues to become more resistant to existing drug regimens resulting in a need for constant innovation on the part of drug researchers. In an article published by Medicalxpress.com which can be found here, researchers are reported to have found a chemical alteration that makes fluoroquinolones, an existing group of TB-fighting drugs, more effective against drug resistant TB. The article provides an in-depth characterization of the TB enzymes targeted by fluoroquinolones and the mutations that cause resistance. The researchers discovered that by creating a critical change in the chemical composition of moxifloxacin, a broad-spectrum fluoroquinolone antibacterial, they were able to overcome the resistance caused by these mutated enzymes. This could mean more effective treatment for TB patients.